



- 1 -

VPI00-115CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kuida et al.,  
Serial No.: 09/922,584  
Filing Date: August 3, 2001  
For: ERK-5 DEFICIENT ANIMALS AND METHODS  
OF INHIBITING ANGIOGENESIS THROUGH  
THE INHIBITION OF ERK-5

Cambridge, Massachusetts  
December 3, 2001

Hon. Assistant Commissioner  
For Patents  
Washington, D.C. 20231

Attention: Application Processing Division,  
Special Processing and Correspondence  
Branch

TRANSMITTAL LETTER FOR CORRECTED FIGURES AND SEQUENCE  
LISTING AND DISKETTE


Sir:


Transmitted herewith in response to the Notice  
Of Incomplete Nonprovisional Application - Filing Date  
Not Granted, mailed October 3, 2001, are the following  
materials relating to the above-identified application:

1. Statement under 37 C.F.R. 1.82.1  
Certification of Sequence Listing
2. Diskette containing Sequence Listing  
and paper copy of sequence list
3. Replacement Figures 1 thru 6
4. Copy of Notice Of Incomplete  
Nonprovisional Application - Filing  
Date Not Granted;

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

  
Andrea L.C. Robidoux (Reg. No. 47,902)  
Agent for Applicants  
Vertex Pharmaceuticals Inc.  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617) 444-6731  
Fax.: (617) 444-6483



**Certificate Of Mailing Under 37 CFR 1.10**

Express Mailing No. ET795387771US Date of Deposit December 3, 2001

I hereby certify that this document/application is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202


1. Transmittal of Notice to File Missing Parts
2. Verified Statement under 37 CFR 1.821 (f)
3. Sequence Listing (Paper Copy)
4. Sequence Diskette
5. Replacement Figures 1-6
6. Certificate of Mailing
7. Return Receipt Postcard

Angela J. Billings

(type or printed name of person mailing document/applications)

(signature of person mailing document/application)

VPI/00-115 CIP



- 1 -

VPI00-115 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kuida et al.,  
Serial No.: 09/922,584  
Filing Date: August 3, 2001  
For: ERK-5 DEFICIENT ANIMALS AND METHODS  
OF INHIBITING ANGIOGENESIS THROUGH  
THE INHIBITION OF ERK-5

Cambridge, Massachusetts  
December 3, 2001

Hon. Assistant Commissioner  
For Patents  
Washington, D.C. 20231

Attention: Application Processing Division,  
Special Processing and Correspondence  
Branch

TRANSMITTAL LETTER FOR CORRECTED DRAWINGS AND SEQUENCE  
LISTING AND DISKETTE


Sir:

Transmitted herewith in response to the Notice  
Of Incomplete Nonprovisional Application - Filing Date  
Not Granted, mailed October 3, 2001, are the following  
materials relating to the above-identified application:

1. Statement under 37 C.F.R. 1.82.1  
Certification of Sequence Listing
2. Diskette containing Sequence Listing  
and paper copy of sequence list
3. Corrected Figures 1 thru 6
4. Copy of Notice Of Incomplete  
Nonprovisional Application - Filing  
Date Not Granted;

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

  
\_\_\_\_\_  
Andréa L.C. Robidoux (Reg. No. 47,902)  
Agent for Applicants  
Vertex Pharmaceuticals Inc.  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617) 444-6731  
Fax.: (617) 444-6483